Skip to content

CREDOPHAR: what changed

BE 0849.730.193NACE 46.460, Wholesale of pharmaceutical and medical goodsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€51,670
2024 · -€182,309+€233,979
Equity
€1.9m
2024 · €1.9m+€51,670
Cash
-
not filed
Balance sheet total
€7.8m
2024 · €7.6m+€200,276

Largest movements

2024 to 2025
Assets
  • Receivables within one year +€211,205

    up €211,205 (+25.9%), from €815,299 to €1.0m

    of which Trade receivables: +€214,427

Equity and liabilities
  • Accrued charges and deferred income +€210,848

    up €210,848 (+84.1%), from €250,697 to €461,544

  • Trade debts -€152,026

    down €152,026 (-59.3%), from €256,319 to €104,292

  • Other debts +€107,961

    up €107,961 (+2.1%), from €5.2m to €5.3m

Income statement
  • Gross operating margin +€147,732

    up €147,732 (+134%), from €109,990 to €257,722

  • Financial charges -€40,148

    down €40,148 (-16.0%), from €251,491 to €211,343

  • Other operating charges -€37,143

    down €37,143 (-93.4%), from €39,770 to €2,627

  • Write-downs -€21,803

    down €21,803, from €1,803 to -€20,000

  • Taxes +€12,176

    up €12,176, from €0 to €12,176

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 -€182,309
Gross operating margin +€147,732
Write-downs +€21,803
Other operating charges +€37,143
Financial income -€671
Financial charges +€40,148
Taxes -€12,176
Result 2025 €51,670
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

Cash or the result is not a separate line in both sets of accounts. So the cash flow cannot be derived from them.

Every line side by side 34 lines
Line Code 2024 2025 Change %
Total assets 20/58 €7,640,451 €7,840,727 +€200,276 +2.6%
Fixed assets 21/28 €6,814,028 €6,814,028 = 0.0%
Financial fixed assets 28 €6,814,028 €6,814,028 = 0.0%
Current assets 29/58 €826,423 €1,026,699 +€200,276 +24.2%
Amounts receivable within one year 40/41 €815,299 €1,026,503 +€211,205 +25.9%
Trade receivables 40 €812,076 €1,026,503 +€214,427 +26.4%
Other amounts receivable 41 €3,223 - -€3,223
Deferred charges and accrued income 490/1 €11,124 €196 -€10,928 -98.2%
Total equity and liabilities 10/49 €7,640,451 €7,840,727 +€200,276 +2.6%
Equity 10/15 €1,878,850 €1,930,520 +€51,670 +2.8%
Contributions 10/11 €20,522 €20,522 = 0.0%
Profit (loss) carried forward 14 €1,858,328 €1,909,998 +€51,670 +2.8%
Amounts payable 17/49 €5,761,601 €5,910,208 +€148,606 +2.6%
Amounts payable within one year 42/48 €5,510,905 €5,448,663 -€62,241 -1.1%
Financial debts 43 €0 - =
Credit institutions 430/8 €0 - =
Trade debts 44 €256,319 €104,292 -€152,026 -59.3%
Suppliers 440/4 €256,319 €104,292 -€152,026 -59.3%
Taxes, remuneration and social security 45 €68,636 €50,460 -€18,176 -26.5%
Taxes 450/3 €68,636 €50,460 -€18,176 -26.5%
Other amounts payable 47/48 €5,185,950 €5,293,911 +€107,961 +2.1%
Accrued charges and deferred income 492/3 €250,697 €461,544 +€210,848 +84.1%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) 631/4 €1,803 -€20,000 -€21,803
Other operating charges 640/8 €39,770 €2,627 -€37,143 -93.4%
Gross operating margin 9900 €109,990 €257,722 +€147,732 +134%
Operating profit (loss) 9901 €68,417 €275,095 +€206,678 +302%
Financial income 75/76B €765 €94 -€671 -87.7%
Recurring financial income 75 €765 €94 -€671 -87.7%
Financial charges 65/66B €251,491 €211,343 -€40,148 -16.0%
Recurring financial charges 65 €251,491 €211,343 -€40,148 -16.0%
Profit (loss) for the period before taxes 9903 -€182,309 €63,846 +€246,156
Income taxes 67/77 €0 €12,176 +€12,176
Profit (loss) for the period 9904 -€182,309 €51,670 +€233,979
Profit (loss) for the period to be appropriated 9905 -€182,309 €51,670 +€233,979

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€1.1m to €1.1m

Midpoint €1.1m · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Adjusted equity €1.9m
Capitalised earnings €184,600 to €258,440
Indication €1.1m to €1.1m

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€1,930,520
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€1.9m

Capitalised earnings

net result for the year (9904)
2025
€51,670
2024
-€182,309
2023
€200,688
excluding non-recurring income and charges
€208,170
2022
€320,180
excluding non-recurring income and charges
€353,141
2021
€686,939
Average result, excluding non-recurring income and charges
€25,844
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€184,600 / €215,367 / €258,440

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.